| Benjamin Apgar, LCSW | |
|
354 Waverly St, Framingham, MA 01702-7079 | |
| (508) 661-2020 | |
| Not Available |
| Full Name | Benjamin Apgar |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 354 Waverly St, Framingham, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053786889 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 219554 (Massachusetts) | Primary |
| Entity Name | Mt Auburn Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992750996 PECOS PAC ID: 6103725031 Enrollment ID: O20040527001374 |
News Archive
UConn associate professor of pharmaceutics Xiuling Lu, along with professor of chemistry Rajeswari M. Kasi, was part of a team that recently published a paper in Nature Cell Biology finding a commonly used chemotherapy drug may be repurposed as a treatment for resurgent or chemotherapy-resistant leukemia.
As a testament to Governor Andrew Cuomo's leadership in developing an unparalleled research and development ecosystem in New York State, Sara Brenner, MD, MPH and her colleagues at SUNY Polytechnic Institute (SUNY Poly), the George Washington School of Medicine and Health Sciences, and Stony Brook University have demonstrated a novel method for the rapid visualization and identification of engineered nanoparticles in tissues.
A team of French and German researchers report in the May 2008 print issue of The FASEB Journal that people with limb-girdle muscular dystrophy are missing a protein called c-FLIP, which the body uses to prevent the loss of muscle tissue.
An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin Apgar, LCSW 354 Waverly St, Framingham, MA 01702-7079 Ph: (508) 661-2020 | Benjamin Apgar, LCSW 354 Waverly St, Framingham, MA 01702-7079 Ph: (508) 661-2020 |
News Archive
UConn associate professor of pharmaceutics Xiuling Lu, along with professor of chemistry Rajeswari M. Kasi, was part of a team that recently published a paper in Nature Cell Biology finding a commonly used chemotherapy drug may be repurposed as a treatment for resurgent or chemotherapy-resistant leukemia.
As a testament to Governor Andrew Cuomo's leadership in developing an unparalleled research and development ecosystem in New York State, Sara Brenner, MD, MPH and her colleagues at SUNY Polytechnic Institute (SUNY Poly), the George Washington School of Medicine and Health Sciences, and Stony Brook University have demonstrated a novel method for the rapid visualization and identification of engineered nanoparticles in tissues.
A team of French and German researchers report in the May 2008 print issue of The FASEB Journal that people with limb-girdle muscular dystrophy are missing a protein called c-FLIP, which the body uses to prevent the loss of muscle tissue.
An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
› Verified 1 days ago
Phillip D. Turner, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 300 Howard St, Framingham, MA 01702 Phone: 508-879-2250 Fax: 508-620-2637 | |
Mellissa J Rearick, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 99 Lincoln St, Cancer Care Center, Framingham, MA 01702 Phone: 508-383-8529 Fax: 508-383-8584 | |
Ms. Malka Alpert Young, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 475 Franklin St, Suite 101, Framingham, MA 01702 Phone: 508-875-3100 Fax: 508-875-4373 | |
Claire Comeau, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 300 Howard St, Framingham, MA 01702 Phone: 508-879-2250 | |
Ms. Rebecca Jill Robbins, MSW, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 88 Lincoln St, Wayside Youth And Family Support Network, Framingham, MA 01702 Phone: 508-620-0010 | |
Emma Fiege, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1881 Worcester Rd, Framingham, MA 01701 Phone: 508-628-6300 | |
Ms. Pauline Frances Gleason, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 40 Speen St, Ste 105, Framingham, MA 01701 Phone: 508-620-1655 Fax: 509-620-0418 |